[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Mbx Biosciences Inc (MBX)

Mbx Biosciences Inc (MBX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,544,555
  • Shares Outstanding, K 47,598
  • Annual Sales, $ 0 K
  • Annual Income, $ -86,970 K
  • EBIT $ -99 M
  • EBITDA $ -99 M
  • 60-Month Beta 0.78
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.84

Options Overview Details

View History
  • Implied Volatility 115.72% (+1.27%)
  • Historical Volatility 85.65%
  • IV Percentile 60%
  • IV Rank 16.44%
  • IV High 309.05% on 07/18/25
  • IV Low 77.70% on 10/24/25
  • Expected Move (DTE 31) 7.65 (24.69%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 161
  • Volume Avg (30-Day) 114
  • Put/Call OI Ratio 0.15
  • Today's Open Interest 1,510
  • Open Int (30-Day) 1,931
  • Expected Range 23.33 to 38.63

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.66
  • Number of Estimates 4
  • High Estimate $-0.60
  • Low Estimate $-0.79
  • Prior Year $-0.58
  • Growth Rate Est. (year over year) -13.79%

Price Performance

See More
Period Period Low Period High Performance
1-Month
27.56 +12.41%
on 04/29/26
45.85 -32.43%
on 05/11/26
-2.79 (-8.26%)
since 04/17/26
3-Month
26.14 +18.52%
on 03/30/26
45.85 -32.43%
on 05/11/26
-9.33 (-23.15%)
since 02/18/26
52-Week
9.43 +228.53%
on 06/20/25
45.85 -32.43%
on 05/11/26
+19.82 (+177.60%)
since 05/16/25

Most Recent Stories

More News
MBX Biosciences Obesity Day Spotlights Monthly GLP-1 Hope and Pipeline Push

MBX Biosciences (NASDAQ:MBX) used its Obesity Day event to outline preliminary clinical data for its lead obesity candidate MBX 4291, introduce a new preclinical obesity program and reiterate key development...

MBX : 30.98 (-4.53%)
MBX Biosciences Provides Obesity Portfolio Update Including Initial Phase 1 Data for MBX 4291 Supporting Potential for Once-Monthly Dosing

Preliminary blinded data from ongoing Phase 1 trial demonstrated mean weight loss of 7% (range 0-16%) at 8 weeks in first MAD Part B cohort (n=8, including 2 placebo) MBX 4291 generally well tolerated,...

MBX : 30.98 (-4.53%)
MBX Biosciences: Can Platform Validation Wait Until Late 2026 Without a Differentiation Problem?

Barchart Research What to Expect from MBX Earnings MBX Generated May 8, 2026 Current Price $40.97 EPS Estimate $$-0.68 Consensus Rating Strong Buy Average Move 4.47% MBX Biosciences: Can Platform Validation...

MBX : 30.98 (-4.53%)
MBX Biosciences Reports First Quarter 2026 Financial Results and Corporate Highlights

Results from Phase 2 trial of once-weekly canvuparatide accepted for oral presentation at ENDO in June 2026 Phase 3 trial of once-weekly canvuparatide on track to initiate in Q3 2026 Appointment...

MBX : 30.98 (-4.53%)
MBX Biosciences Announces Appointment of Mark Soued as Chief Commercial Officer and Inducement Grant Award

CARMEL, Ind. and BURLINGTON, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization...

MBX : 30.98 (-4.53%)
MBX Biosciences to Host In-Person and Virtual Obesity Day on May 11, 2026 to Discuss Expanding Obesity Portfolio

CARMEL, Ind. and BURLINGTON, Mass., April 23, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization...

MBX : 30.98 (-4.53%)
MBX Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

CARMEL, Ind., April 03, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision...

MBX : 30.98 (-4.53%)
MBX Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Highlights

Phase 3 trial of once-weekly canvuparatide remains on track to initiate in Q3 2026 following recently completed, successful End-of-Phase 2 meeting with FDA 12-week MAD Phase 1 data from MBX 4291...

MBX : 30.98 (-4.53%)
MBX Biosciences Appoints Karen Basbaum as Chief Business Officer

CARMEL, Ind., March 10, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision...

MBX : 30.98 (-4.53%)
CORRECTING & REPLACING -- MBX Biosciences Announces Successful End-of-Phase 2 FDA Meeting and Provides Phase 3 Development Plan for Once-Weekly Canvuparatide for Hypoparathyroidism

In the fourth paragraph, we are replacing  milligrams with micrograms . The corrected press release follows. CARMEL, Ind., March 09, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX),...

MBX : 30.98 (-4.53%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

MBX Biosciences Inc. is a clinical-stage biopharmaceutical company. It focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company's pipeline includes its lead product candidate MBX 2109, MBX 1416 and MBX 4291. MBX...

See More

Key Turning Points

3rd Resistance Point 35.06
2nd Resistance Point 34.08
1st Resistance Point 32.53
Last Price 30.98
1st Support Level 30.00
2nd Support Level 29.03
3rd Support Level 27.48

See More

52-Week High 45.85
Fibonacci 61.8% 31.94
Last Price 30.98
Fibonacci 50% 27.64
Fibonacci 38.2% 23.34
52-Week Low 9.43

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.